Development of an algorithm for adjudicating actionable hemorrhage in pediatric trauma patients.

J Trauma Acute Care Surg

From the Division of Trauma and Burn Surgery (M.S.K., G.J.S., T.M.S., A.H.M., R.S.B.), Children's National Hospital, Washington, DC; Division of Pediatric Surgery (N.J.A., A.M.G., A.R.J.), University of California San Francisco Benioff Children's Hospitals, San Francisco; Department of Surgery (N.J.A., A.M.G.), University of California, San Francisco, East Bay, Oakland, California; Division of Emergency Medicine (S.J.R., J.C.L.) and Division of Pediatric Surgery (K.L.G.), Nationwide Children's Hospital; Ohio State University College of Medicine (K.L.G., J.C.L.), Columbus, Ohio; and Department of Surgery (A.R.J.), University of California San Francisco, San Francisco, California.

Published: March 2025

Background: Bleeding is the leading cause of preventable death in trauma. Early identification of hemorrhage improves patient outcomes. Current triage tools for predicting hemorrhage rely on transfusion receipt as a surrogate outcome, indicating that blood was needed. This outcome does not account for misclassification of patients who receive prompt hemorrhage control procedure (HCP) without transfusion, patients who die before transfusion receipt, or those who receive unnecessary transfusion. Objective criteria that do not rely on transfusion receipt alone are needed to more accurately determine actionable hemorrhage and the appropriateness of transfusions in pediatric trauma patients.

Methods: We defined actionable hemorrhage within 6 hours of emergency department arrival as (1) actual or (2) estimated pretransfusion hemoglobin <8 g/dL, (3) performance of an HCP irrespective of transfusion receipt, or (4) death within 24 hours with an autopsy supporting bleeding as the cause of death. We applied this algorithm to 4,371 children (younger than 18 years) treated for blunt or penetrating injuries at three level 1 pediatric trauma centers between 2019 and 2021.

Results: A total of 4,201 children (96.1%) did not have actionable hemorrhage. One hundred sixty-four (3.8%) met the criteria for actionable hemorrhage, including 129 who were transfused within 6 hours. Transfusion receipt alone as an outcome missed 35 of 164 children (21.3%) with actionable hemorrhage: 19 who underwent an HCP and 16 with a hemoglobin level of <8 g/dL but not transfused within 6 hours. Thirty-eight of 167 children (22.8%) who received transfusion within 6 hours did not have actionable hemorrhage. Transfusion receipt as a test for actionable hemorrhage had a sensitivity of 78.7%, specificity of 99.1%, positive predictive value of 77.2%, negative predictive value of 99.2%, and Matthews correlation coefficient of 0.77.

Conclusion: Relying on transfusion receipt as a surrogate for actionable hemorrhage both underestimates and overestimates the actual need for intervention for hemorrhage. This study supports adjudicating actionable hemorrhage with a structured, criteria-based approach to more accurately ascertain this outcome.

Level Of Evidence: Diagnostic Test and Criteria; Level III.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TA.0000000000004588DOI Listing

Publication Analysis

Top Keywords

actionable hemorrhage
12
transfusion receipt
12
pediatric trauma
8
rely transfusion
8
hemorrhage
6
transfusion
5
development algorithm
4
algorithm adjudicating
4
adjudicating actionable
4
hemorrhage pediatric
4

Similar Publications

and () mutation screening is recommended for patients with advanced breast cancer or early breast cancer suspected to have hereditary origins based on family history or tumor characteristics. Blood-based testing is the standard approach, but it is not feasible in patients who have undergone bone marrow transplantation due to the replacement of blood cells with donor-derived cells. We report a case of a patient who, following bone marrow transplantation, required an alternative to blood-based germline screening.

View Article and Find Full Text PDF

Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion.

View Article and Find Full Text PDF

Background: We investigated mental health diagnoses (MHDs) in mycosis fungoides (MF) patients compared to the general population, evaluated risk factors, and studied survival outcomes in a large population database.

Methods: MF patients from the Utah Cancer Registry diagnosed from 2001 to 2014 were matched with up to five general population individuals from the Utah Population Database. MHDs were retrospectively tracked in both populations (median follow-up = 6.

View Article and Find Full Text PDF

This report aimed to investigate the relationship between cerebral hemodynamics and orthostatic hypotension (OH) in a patient with acute exacerbation of chronic heart failure (HF) by measuring oxyhemoglobin (OHb) and regional cerebral oxygen saturation (rSO) using the wearable near-infrared spectroscopy (NIRS) device for risk management. A 61-year-old man was diagnosed with acute exacerbation of chronic HF. The patient was admitted to the hospital for the first time on day 0, and the first NIRS was performed on day 9.

View Article and Find Full Text PDF

Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe.

Lancet Haematol

March 2025

Deptartment of Medicine 3, Haematology and Oncology, University Hospital Regensburg, Regensburg, Germany; Department for Epidemiology and Preventive Medicine, Division of Medical Sociology, University of Regensburg, Regensburg, Germany; Bavarian Cancer Research Center, Regensburg, Germany.

Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand how to improve the field of GVHD research, management, and care, the cGVHD Eurograft Initiative organised a European community advisory board of patient advocates, with the assistance of the Lymphoma Coalition, to identify unmet needs. We present the results of this project in this Viewpoint, which identify unmet GVHD needs from the patient advocates' perspectives and provide five key actionable themes to improve GVHD management and care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!